We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HLMA:LSEHalma plc Analysis

Data as of 2026-06-13 - not real-time

£3,898.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Halma plc is riding a mixed technical landscape: the price sits just above the computed support of 3,808 GBp and the 20‑day SMA sits near 4,561 GBp, leaving the stock in a discount to its short‑term averages. Momentum indicators are bearish – the MACD line is negative and the histogram deep in red, while the RSI of 28 signals oversold conditions that could trigger a bounce. Fundamentally, the company delivered a 14.6% revenue surge, healthy operating margins of 20.6%, and a solid ROE of 18%, supporting the case for a longer‑run recovery. Recent headlines, however, highlight sharp price drops of 11‑14% despite earnings beating expectations, underscoring heightened short‑term sentiment risk. With a low beta of 0.57 but a 30‑day volatility of 57%, the stock combines modest market‑risk exposure with pronounced price swings, while the dividend yield of 0.63% and a payout ratio of 25% appear sustainable. Overall, the blend of strong growth fundamentals and a currently bearish technical setup suggests a cautious hold in the near term, with upside potential if the price stabilises above support and the market digests the earnings narrative.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Recent 11‑14% price plunge despite earnings beat
  • Bearish MACD and price near support
  • Oversold RSI indicating potential volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • 14.6% revenue growth and strong operating margins
  • Sustainable dividend with low payout ratio
  • Improving forward PE relative to current valuation

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Diversified safety, environmental and healthcare portfolio
  • Robust ROE and cash flow generation
  • Global exposure reducing single‑region concentration risk

Key Metrics & Analysis

Financial Health

Revenue Growth14.60%
Profit Margin14.42%
P/E Ratio42.4
ROE18.31%
ROA9.51%
Debt/Equity42.13
P/B Ratio6.8
Op. Cash Flow£480.6M
Free Cash Flow£261.2M
Industry P/E30.6

Technical Analysis

TrendBullish
RSI28.0
Support£3,808.00
Resistance£4,902.00
MA 20£4,561.20
MA 50£4,430.66
MA 200£3,796.87
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Fair Value£1,477.43
Target Price£4,377.50
Upside/Downside12.30%
GradeFair
TypeBlend
Dividend Yield0.63%

Risk Assessment

Beta0.57
Volatility57.01%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.